N/A
Completed N=15
Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis
Source: ClinicalTrials.gov NCT00769184 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Aug 2015
Primary outcomePrimary: Percentage of Patients Who Are Clear (PGA Score 0) or Have Minimal Disease (PGA Score 1) on Each Treated Side at Each Visit. — 33.3; 6.7; 46.2; 15.4 percentage of participants
Summary
This is a 12 week bilateral study, consisting of 6 weeks of treatment and 6 weeks of follow-up. The purpose of the study is to compare the safety and effectiveness of combining and then following a high potency topical corticosteroid treatment with LCD treatment for moderate-to-severe localized plaque psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Patients Who Are Clear (PGA Score 0) or Have Minimal Disease (PGA Score 1) on Each Treated Side at Each Visit. |
33.3; 6.7; 46.2; 15.4; 25.0; 16.7 | — |
| SECONDARY Mean Percent Improvement in Disease Severity Using PGA and OTLS Scores of Target Lesions |
39; 34; 47; 25; 31; 12 | — |
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- able to provide written informed consent
- able to attend study visits, apply medications, and follow instructions
- moderate to severe localized plaque psoriasis lesions (<10% BSA on each side of the body)
Exclusion Criteria
- other current treatments for psoriasis
- hypersensitivity to steroids, liquor carbonis detergens, alcohol, fragrance
- pregnant or nursing
Data sourced from ClinicalTrials.gov (NCT00769184). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.